Altimmune
Market cap $298M 194.6M shares (10-Q, Nov 6, 2026) × $1.53 close Nov 17, 2026
Most recent annual filing: 2026-03-15
- AUD program corporate updateDec 2026AUD program corporate update, Dec 2026, notable
Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.
Pipeline (3 active programs)
Capital (as filed)
- Cash
- $28.9M cash and cash equivalents · Sep 30, 2026 (10-Q)
- Short-term investments
- $236M Sep 30, 2026
- Long-term investments
- $215M Sep 30, 2026
- Operating cash flow
- −$37.7M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
- As stated in coverage
- $480M cash per the update of Nov 12, 2026 — the company's own words as read there, not the filed figure
Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.
Biotech Distilled coverage (14)
- 2026-11-13 UPDATE: Altimmune (ALT) - The Market Now Values the Pipeline Below Zero 🔒 Paid
- 2026-11-10 UPDATE: Altimmune (ALT) - The AUD Binary Finally Has a Date 🔒 Paid
- 2026-08-13 UPDATE: Altimmune (ALT) - The Q2 Print Quietly Moves a Catalyst 🔒 Paid
- 2026-08-04 UPDATE: Altimmune (ALT) - PERFORMA Is Live, and the Protocol Answers the Tolerability Question 🔒 Paid
- 2026-07-28 UPDATE: Altimmune (ALT) - The 2.4 mg Dose Just Answered the Question I Asked in December 🔒 Paid
- 2026-05-27 UPDATE: Altimmune (ALT) - The Biopsy Data Finally Shows Up
- 2026-05-02 UPDATE: Altimmune (ALT) - The Second Whale Surfaces 🔒 Paid
- 2026-05-01 UPDATE: Altimmune (ALT) - Deep Track Just Showed Its Cards 🔒 Paid
- 2026-04-27 UPDATE: Altimmune (ALT) - The $4.40 Floor Just Became a $3.00 Ceiling 🔒 Paid
- 2026-03-21 UPDATE: Altimmune (ALT) - 400 Million Shares?
- 2026-03-07 UPDATE: Altimmune (ALT) - The $340M War Chest and the Phase 3 Blueprint
- 2026-01-30 UPDATE: Altimmune (ALT) – The Smart Money Bailout
- 2026-01-05 UPDATE: The FDA Just Blinked (In a Good Way) – Altimmune Derisked?
- 2025-12-19 Altimmune, Inc. (ALT): Scientific Due Diligence for Lead and Pipeline Indications
Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.
Verdict history (14 calls)
Every verdict Biotech Distilled has published on Altimmune, oldest first — the full history, never a selection. How calls are scored: the track record.
- 2025-12-19 Watch Altimmune, Inc. (ALT): Scientific Due Diligence for Lead and Pipeline Indications Pemvidutide may be a niche MASH drug with significant financing risk; wait for January FDA minutes before taking a position.
- 2026-01-05 Speculative buy speculative UPDATE: The FDA Just Blinked (In a Good Way) – Altimmune Derisked? FDA Breakthrough Therapy Designation and Phase 3 alignment with flexible dosing and AI pathology removes the doomsday regulatory scenario, de-risking the story enough for a speculative entry.
- 2026-01-30 Buy core UPDATE: Altimmune (ALT) – The Smart Money Bailout A $75M raise anchored by a single high-conviction institutional investor removes existential financing risk and sets a $4.40 institutional floor, shifting risk/reward heavily to the upside.
- 2026-03-07 Buy core UPDATE: Altimmune (ALT) - The $340M War Chest and the Phase 3 Blueprint With $340M in cash, FDA-aligned Phase 3 blueprint confirmed, and a sell-the-news dip to $3.57, the fundamentals remain strong and the dip represents an accumulation opportunity.
- 2026-03-21 Buy core UPDATE: Altimmune (ALT) - 400 Million Shares? The proxy's authorized share increase is a necessary administrative move for Phase 3 flexibility, not an imminent dilution event; insider buying and $340M cash support maintaining the position.
- 2026-04-27 Hold UPDATE: Altimmune (ALT) - The $4.40 Floor Just Became a $3.00 Ceiling A $225M offering at $3.00 with 75M warrant overhang and a 50% share count increase invalidates the $4.40 institutional floor thesis and caps post-readout upside, making this dead money for ~3 years.
- 2026-04-30 Speculative buy speculative UPDATE: Altimmune (ALT) - Deep Track Just Showed Its Cards Deep Track Capital's disclosed 9.99% position — including 30M of the 75M warrants — confirms a named healthcare specialist is sized maximally on the long side, partially rehabilitating the April dilution narrative.
- 2026-05-01 Speculative buy speculative UPDATE: Altimmune (ALT) - The Second Whale Surfaces TCG Crossover's 9.8% position alongside Deep Track means two top-tier biotech specialists hold ~20% of the company and 53% of the warrant overhang, confirming a syndicated anchor rather than a single opportunistic bet.
- 2026-05-27 Speculative buy speculative UPDATE: Altimmune (ALT) - The Biopsy Data Finally Shows Up EASL qFibrosis data showing clean AI-quantified histological fibrosis regression at 24 weeks partially rebuts the 'biopsy missed' bear case from December, strengthening the thesis without re-rating the stock.
- 2026-07-28 Buy core UPDATE: Altimmune (ALT) - The 2.4 mg Dose Just Answered the Question I Asked in December RECLAIM's clean Phase 2 primary at p=0.0014 with corroborating PEth biomarker and 9.1% placebo-adjusted weight loss at 2.4 mg confirms the under-dosing thesis and gives pemvidutide a genuine second registrational path in AUD.
- 2026-08-04 Buy core UPDATE: Altimmune (ALT) - PERFORMA Is Live, and the Protocol Answers the Tolerability Question PERFORMA Phase 3 initiation on schedule with a titration protocol addressing RECLAIM's 10% drug-related discontinuation rate and AIM-MASH AI Assist formally integrated confirms execution and de-risks tolerability.
- 2026-08-13 Buy core UPDATE: Altimmune (ALT) - The Q2 Print Quietly Moves a Catalyst $519M cash with zero ATM usage in Q2 confirms runway through Phase 3 readout; RESTORE endpoint shift to Week 48 is biologically defensible though it thins the near-term catalyst calendar.
- 2026-11-10 Buy core UPDATE: Altimmune (ALT) - The AUD Binary Finally Has a Date Full RECLAIM dataset survives sensitivity analysis with near-doubled abstinence days and confirmed PEth biomarker; FDA AUD End-of-Phase 2 meeting set for December makes the next binary imminent.
- 2026-11-13 Buy core UPDATE: Altimmune (ALT) - The Market Now Values the Pipeline Below Zero Stock trading below net cash (~$435M) assigns negative value to a BTD Phase 3 MASH asset plus positive AUD Phase 2, creating a compelling setup ahead of December's FDA EOP2 meeting despite rising PERFORMA spend.
- Long call · opened Jan 5, 2026 at $4.09 · -62.6% vs XBI +20.9% (Nov 17, 2026)
Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.
Filings & releases (37)
SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from May 6, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →
- Nov 12, 2026ReleaseAltimmune Announces Publication of IMPACT Phase 2b 48-Week Data in MASH in The Lancet Gastroenterology & Hepatology→ BD updateSummary on the 8-K
- Nov 12, 2026ReleaseAltimmune Announces Third Quarter 2026 Financial Results and Business Update→ BD updateSummary on the 8-K
- Nov 12, 20268-KCurrent report: results of operations · EX-99.1→ BD updateALT dropped 16.6% on Q3 earnings day despite solid science and $480M in cash — the market is pricing accelerating PERFORMA burn, a CMO selling plan, and a stock now 46% below the April offering price, even as the IMPACT data earns a Lancet publication and the December AUD FDA meeting looms.
- Nov 12, 202610-QQuarterly report→ BD updateSummary on the 8-K
- Nov 9, 2026ReleaseAltimmune Presents Positive Late-Breaking Pemvidutide Data at AASLD The Liver Meeting® 2026 in Patients with Alcohol Use Disorder→ BD updateThe full RECLAIM dataset lands at AASLD as a late-breaker — cleaner than the July topline, with a new FIB-4 normalization signal and, more importantly, a December FDA End-of-Phase 2 meeting now formally on the calendar for the AUD Phase 3 program.
- Nov 5, 2026ReleaseAltimmune to Report Third Quarter 2026 Financial Results and Provide Business Update on November 12, 2026
- Nov 5, 2026ReleaseAltimmune Announces Data from RECLAIM Phase 2 Trial of Pemvidutide in Alcohol Use Disorder Selected as Late-Breaking Oral Presentation at AASLD The Liver Meeting® 2026
- Oct 29, 20268-KCurrent report: debt / obligation
- Oct 27, 2026ReleaseAltimmune Appoints Peter Greenleaf and Alex Howarth, Two Leading Biotech Executives, to Board of Directors to Support Its Strategic Evolution
- Oct 27, 20268-KCurrent report: officer / director change, Reg FD disclosure · EX-99.1 EXHIBIT 99.1
- Oct 19, 2026ReleaseAltimmune to Present New Data on Pemvidutide in Serious Liver Diseases at AASLD The Liver Meeting® 2026BD extracted 1 program update from this document → ALT pipeline
- Sep 29, 20268-KCurrent report: officer / director change
- Sep 23, 2026ReleaseAltimmune to Participate in Stifel Cardiometabolic Forum
- Sep 3, 2026ReleaseAltimmune to Participate in the Wells Fargo 21st Annual Healthcare Conference
- Aug 12, 2026ReleaseAltimmune Announces Second Quarter 2026 Financial Results and Business Update
- Aug 12, 20268-KCurrent report: results of operations · EX-99.1BD extracted 1 program update from this document → ALT pipeline
- Aug 12, 202610-QQuarterly report
- Aug 5, 2026ReleaseAltimmune to Report Second Quarter 2026 Financial Results and Provide Business Update on August 12, 2026
- Aug 3, 2026ReleaseAltimmune Initiates PERFORMA Phase 3 Trial of Pemvidutide in Patients with MASHBD extracted 1 program update from this document → ALT pipeline
- Jul 28, 2026ReleaseAltimmune Announces Positive Topline Results from RECLAIM Phase 2 Trial of Pemvidutide in Alcohol Use Disorder
- Jul 28, 20268-KCurrent report: Reg FD disclosure, other events · EX-99.1BD extracted 1 program update from this document → ALT pipeline
- Jun 16, 20268-KCurrent report: other events
- May 28, 2026ReleasePemvidutide Demonstrates Significant Metabolic Improvements in Patients with MASH in New 48‑Week IMPACT Phase 2b Data Presented at EASL 2026
- May 27, 2026ReleaseNew IMPACT Phase 2b Data Highlight Concurrent Improvements Across Multiple Non-Invasive Markers and qFibrosis-Measured Fibrosis Regression with Pemvidutide in MASH at EASL 2026
- May 27, 2026ReleaseAltimmune to Participate in Upcoming Investor Conferences
- May 13, 2026ReleaseAltimmune to Present Results of Pemvidutide in MASH in an Oral Presentation and Multiple Poster Presentations at EASL Congress 2026
- May 13, 2026ReleaseAltimmune Announces First Quarter 2026 Financial Results and Business Update
- May 13, 20268-KCurrent report: results of operations · EX-99.1
- May 13, 202610-QQuarterly report
- May 6, 2026ReleaseAltimmune to Report First Quarter 2026 Financial Results and Provide Business Update on May 13, 2026
- Apr 24, 20268-KCurrent report: material agreement
- Apr 24, 2026424B5Prospectus supplement (offering)
- Apr 22, 2026424B5Prospectus supplement (offering)
- Apr 16, 20268-KCurrent report: charter / bylaws / fiscal year, shareholder vote
- Mar 17, 2026DEF 14AProxy statement
- Mar 6, 202610-KAnnual report
- Mar 5, 20268-KCurrent report: results of operations · EX-99.1
13 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)
- Nov 16, 2026SCHEDULE 13G/A13G amendment
- Nov 10, 2026SCHEDULE 13GPassive >5% holder (13G)
- May 15, 2026SCHEDULE 13G/A13G amendment
- May 13, 2026S-8Employee plan registration
- May 12, 2026SCHEDULE 13GPassive >5% holder (13G)
- May 1, 2026SCHEDULE 13GPassive >5% holder (13G)
- May 1, 2026SCHEDULE 13GPassive >5% holder (13G)
- May 1, 2026SCHEDULE 13GPassive >5% holder (13G)
- Apr 30, 2026SCHEDULE 13GPassive >5% holder (13G)
- Apr 22, 2026S-3MEFS-3MEF
- Mar 26, 2026SCHEDULE 13G/A13G amendment
- Mar 17, 2026ARSAnnual report to shareholders
- Mar 6, 2026PRE 14APRE 14A